2020
DOI: 10.1111/dth.14186
View full text
|
Sign up to set email alerts
|
Share

Abstract: With the emergence of the coronavirus disease 2019 (COVID-19) pandemic, concern has risen among physicians if treatment with biologic agents for psoriasis may result in a more severe disease course. 1,2 To date, only a limited number of cases have been published on the outcomes of COVID-19 infection in psoriatic patients under guselkumab, ustekinumab, adalimumab and secukinumab treatment, 3-5 yet no such case was reported on patients receiving risankizumab therapy. Here, we report on a 77-year-old male patient…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
2
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals